



Human VEGF Monoclonal Antibody (Research Grade Bevacizumab Biosimilar)

Recombinant Monoclonal Human IgG1 Clone #FB019

Catalog Number: BIO-003

DESCRIPTION

Species Reactivity	Human
Specificity	Detects human VEGF in direct ELISA. This non-therapeutic antibody uses the same variable region sequences (VH, VL) as the therapeutic antibody Bevacizumab. This product is for research use only.
Source	Recombinant Monoclonal Human IgG1 Clone #FB019
Purification	Protein A/G purified from CHO cell culture supernatant
Immunogen	Human VEGF
Endotoxin Level	<0.10 EU per 1 µg of the antibody by the LAL method
Formulation	0.2 µm filtered solution in PBS

APPLICATION

Neutralization	Measured by its ability to neutralize VEGF165-induced proliferation in HUVEC human umbilical vein endothelial cells. The Neutralization Dose (ND50) is typically 10-80 ng/mL in the presence of 10 ng/mL Recombinant Human VEGF165.
----------------	---

PREPARATION AND STORAGE

Reconstitution	Reconstitute at 0.5 mg/ml in sterile 1xPBS
Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at -20 to -70°C
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. <ul style="list-style-type: none">• 12 months from the date or receipt, -20 to -70°C as supplied.• 1 month, 2 to 8°C under sterile conditions

BACKGROUND

Bevacizumab is a monoclonal anti-vascular endothelial growth factor (VEGF) antibody used in combination with antineoplastic agents for the treatment metastatic colorectal cancer; metastatic, unresectable, locally advanced or recurrent non-squamous non-small cell lung cancer; metastatic renal cell carcinoma; metastatic, persistent, or recurrent cervical cancer; primary peritoneal cancer; epithelial ovarian cancer; fallopian tube cancer; breast cancer and recurrent glioblastoma.